---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-290428"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2021-10-04T23:59:59+00:00"
generated_at: "2026-06-28T23:23:39.262364+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# CytomX appoints Alan Ashworth, Ph.D., FRS to Board of Directors as Class III director

## Summary
- Appointment effective Sept 29, 2021, filling a vacancy; term expires at 2024 annual meeting.
- Standard non-employee director compensation, including option for 40,000 shares vesting monthly over 3 years.
- Company will enter into a standard indemnification agreement with Dr. Ashworth.
- No transactions exceeding $120,000 involving Dr. Ashworth; no arrangements for appointment.

## SEC filing metadata
- accession: 0001193125-21-290428
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2021-10-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312521290428/0001193125-21-290428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312521290428/d233551d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-290428
- JSON: https://secwatch.observer/filing/0001193125-21-290428.json
- Plain text: https://secwatch.observer/filing/0001193125-21-290428.txt

## Key facts
- Executive change
  Alan Ashworth was appointed as Class III director at CytomX Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On September 29, 2021, Alan Ashworth, Ph.D., FRS was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective September 29, 2021, as a Class III director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling a vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312521290428/0001193125-21-290428-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.